Omeros price to book ratio OMER

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 3.9×; Nov 2023
9-year median: 9.3×
9-year range: 2.6× to 108×
Peer median: 2.3×

Omeros' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Nov 2023, at 3.9×.

On the days it had one over the last 9 years, its median was 9.3×, from 2.6× in Mar 2023 to 108× in Dec 2017.

Price to book ratio over time

median 9.3×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	3.9×	2.6×	13.2×
2022	7.8×	7.8×	17.3×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	52.1×	52.1×	102×
2017	101×	94.7×	108×
2016	n/m a value too high to mean anything
2015	65.7×	25.8×	100×
2014	89.0×	66.0×	118×
2013	n/m a value too high to mean anything
2012	45.4×	22.5×	45.4×
2011	21.7×	7.0×	22.2×

Against its peers

Companies in Drug Manufacturers - General nearest Omeros' size, closest first, today.

Company	Price to book ratio
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.4×
PCRXPacira BioSciences	2.2×
ANABAnaptysbio	138×
PAHCPhibro Animal Health	4.1×
ANIPANI Pharmaceuticals	2.8×
ABUSArbutus Biopharma	3.2×
COLLCollegium Pharmaceutical	2.4×
HRMYHarmony Biosciences	2.1×
PBHPrestige Consumer Healthcare	1.2×
CRMDCorMedix	1.3×
Peer median	2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Omeros

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.